One patient with MSI-H follicular thyroid cancer reached continuous PR after receiving treatment with Pembrolizumab.[10] Another case of thyroid cancer with BRAF gene mutation benefited from the treatment of Nivolumab.[11] The main reason why the case reported did not receive combined immunotherapy is that its gene detection is MSS type. This evidence concerns the gene BRAF and thyroid gland carcinoma.